JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Recruiting Phase 2 Interventional Study
B-cell Non-Hodgkin's Lymphoma
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
180 (estimated)
Sponsor
Shanghai Junshi Bioscience Co., Ltd. · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

To evaluate the preliminary efficacy of JS203 combined with standard regimens in patients with B-cell Non-Hodgkin's lymphoma

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Patients must meet all of the following inclusion criteria to be enrolled: * Age range: 18 to 80 years old (inclusive), both male and female are acceptable; * ECOG: 0-2; * B-cell non-Hodgkin's lymphoma expressing CD20 antigen that has been pathologically diagnosed; * At least o…
Contacts

Bang.an Peng, Master

13526844722

bang.an_peng@junshipharma.com

CONTACT